治疗前中性粒细胞与淋巴细胞比值可预测艾立布林治疗软组织肉瘤的疗效。

Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.

机构信息

Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan;

出版信息

Anticancer Res. 2021 Jan;41(1):527-532. doi: 10.21873/anticanres.14804.

DOI:10.21873/anticanres.14804

PMID:33419852

Abstract

BACKGROUND

Eribulin is widely used for the treatment of breast cancer and soft-tissue sarcoma (STS). Previous studies identified the pre-treatment absolute lymphocyte count, baseline neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein concentration as potential prognostic markers in patients with breast cancer treated with eribulin. However, prognostic factors for eribulin treatment in patients with STS have not been identified.

PATIENTS AND METHODS

This was a retrospective analysis of data collected prospectively from 53 patients who were treated with eribulin for recurrent or metastatic STS between March 2016 and August 2019. Univariate and multivariate analyses were performed to determine the predictive factors of durable clinical benefit, progression-free survival, and overall survival.

RESULTS

L-Sarcoma histology [hazard ratio (HR)=28.20, 95% confidence intervaI (CI)=1.67-476.00; p=0.021] and pre-treatment NLR <3.0 (HR=9.96, 95% CI=1.28-77.7; p=0.028) were independent factors predictive of durable clinical benefit. In addition, pre-treatment NLR <3.0 (HR=0.34, 95% CI=0.16-0.74; p=0.0059) and male sex (HR=0.23, 95% CI=0.10-0.52; p<0.001) were independent factors predictive of better progression-free survival.

CONCLUSION

This retrospective study found that baseline NLR predicts the efficacy of eribulin for STS.

摘要

背景

依立布林被广泛用于治疗乳腺癌和软组织肉瘤（STS）。先前的研究确定了治疗乳腺癌患者的依立布林前淋巴细胞绝对值、基线中性粒细胞与淋巴细胞比值（NLR）和 C 反应蛋白浓度作为潜在的预后标志物。然而，STS 患者使用依立布林治疗的预后因素尚未确定。

患者和方法

这是一项对 2016 年 3 月至 2019 年 8 月期间使用依立布林治疗复发性或转移性 STS 的 53 例患者前瞻性收集数据的回顾性分析。进行单因素和多因素分析，以确定持久临床获益、无进展生存期和总生存期的预测因素。

结果

L 肉瘤组织学[风险比（HR）=28.20，95%置信区间（CI）=1.67-476.00；p=0.021]和治疗前 NLR<3.0（HR=9.96，95%CI=1.28-77.7；p=0.028）是持久临床获益的独立预测因素。此外，治疗前 NLR<3.0（HR=0.34，95%CI=0.16-0.74；p=0.0059）和男性（HR=0.23，95%CI=0.10-0.52；p<0.001）是无进展生存期更好的独立预测因素。